Table 2

Prespecified adverse event preferred terms, MedDRA version 12.1
Ocular Nonocular
Endophthalmitis Drug hypersensitivity
Panophthalmitis Hypersensitivity
Intraocular pressure, increased Hypersensitivity NOS (v. 5.1)
Ocular hypertension Anaphylactic shock
Glaucoma Anaphylactic reaction
Glaucoma NOS (v. 5.1) Anaphylactoid shock
Glaucoma, traumatic Anaphylactoid reaction
Retinal injury Angioedema
Retinal tear Angioneurotic edema (v. 5.1)
Retinal detachment Blepharitis, allergic
Retinal hemorrhage Dermatitis, contact
Retinal toxicity Dermatitis, allergic
Detachment of retinal pigment epithelium Toxic skin eruption
Retinal pigment epitheliopathy (v. 5.1) Toxic epidermal necrolysis
Eye hemorrhage Lyell syndrome (v. 5.1)
Eye hemorrhage NOS (v. 5.1) Drug eruption
Vitreous hemorrhage Dermatitis medicamentosa (v. 5.1)
Cataract traumatic Erythema
Erythema multiforme Urticaria
Tongue edema Stevens-Johnson syndrome
Pharyngeal edema Stevens-Johnson syndrome (v. 5.1)
Laryngeal edema Rash
Latex allergy Rash NOS (v. 5.1)
Paresthesia oral Skin reaction
Paraesthesia mucosal Acute generalized exanthematous pustulosis
Paraesthesia mucosal NOS (v. 5.1) Drug rash with eosinophilia and systemic symptoms
Antiplatelet Trialists’ Collaboration Events
Cardiovascular Cerebrovascular
Acute myocardial infarction Brain stem infarction
Cardiac arrest Cerebrovascular accident
Cardiac failure congestive Lacunar infarction
Myocardial infarction Cerebral hemorrhage
Retroperitoneal hemorrhage Transient ischemic attack
Sudden death Peripheral vascular thrombosis
Silent myocardial infarction Pulmonary embolism
Coronary artery stenosis Deep vein thrombosis
Acute coronary syndrome Thrombosis
Angina pectoris Ischemia
Angina unstable Ischemia NOS (v. 5.1)

MedDRA: Medical Dictionary for Regulatory Activities.

NOS: not otherwise specified.

V: version.

Dombi et al.

Dombi et al. BMC Ophthalmology 2012 12:37   doi:10.1186/1471-2415-12-37

Open Data